Hepatitis A vaccine

Area of Science:

• Hepatitis A virus (HAV) research
• Vaccinology
• Immunology

Background:

• Hepatitis A remains a public health concern in the US, causing sporadic cases, epidemics, and fatalities.
• Declining natural immunity in the US population (21-33%) necessitates vaccination strategies.
• A killed virus hepatitis A vaccine is now FDA-approved.

Purpose of the Study:

• To evaluate the efficacy and optimal use of the newly approved hepatitis A vaccine.
• To identify key populations for hepatitis A immunization.
• To assess the impact of co-administering immune globulin with the vaccine.

Main Methods:

• The study focuses on the seroconversion rates following a primary dose and a booster shot of the hepatitis A vaccine.
• It compares antibody levels in individuals receiving the vaccine alone versus those receiving it with immune globulin.
• It discusses the implications of current natural immunity levels and suggests cost-effective screening strategies.

Main Results:

• The hepatitis A vaccine achieves 100% seroconversion after a primary dose and a booster 6-12 months later.
• Co-administration of immune globulin with the vaccine reduces ultimate antibody levels by 50% compared to vaccination alone.
• Natural immunity has declined significantly since 1980, with current levels at 21-33%.

Conclusions:

• The new hepatitis A vaccine is highly effective, providing complete seroconversion with a two-dose regimen.
• Avoid co-administration of immune globulin with the vaccine to maximize antibody response.
• Targeted immunization programs for children, travelers, military, and food handlers, along with cost-effective prescreening for those over 40, are recommended.